
Joseph Mikhael
Expert in myeloma from Translational Genomics Research Institute (TGen), Phoenix, AZ, & International Myeloma Foundation, Studio City, CA.
Top 3 podcasts with Joseph Mikhael
Ranked by the Snipd community

Mar 14, 2025 • 28min
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
In this enlightening discussion, Joseph Mikhael, a myeloma expert from TGen and the International Myeloma Foundation, tackles the pressing issues in myeloma treatment. He highlights breakthroughs in managing smoldering myeloma and the unique challenges faced by frail and elderly patients. The conversation also dives into innovative therapies for triple-class refractory disease, and the critical examination of racial disparities in myeloma care. Mikhael’s insights showcase the need for improved access and personalized treatment approaches.

Sep 9, 2024 • 19min
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
Lalit Kumar, an expert in blood cancer management from Artemis Hospital in India, discusses the challenges of diagnosis and treatment in rural areas. Joseph Mikhael, from the Translational Genomics Research Institute, highlights racial disparities in multiple myeloma treatment in the U.S., emphasizing the need for education and trust. Other guests address socioeconomic barriers in clinical trial recruitment and the stark differences in care accessibility for chronic lymphocytic leukemia across various income countries, advocating for more equitable healthcare options.

Oct 18, 2023 • 1h 20min
Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences
Dr Joseph Mikhael discusses updates in multiple myeloma management, including the concept of stopping treatment for patients with deep responses, the use of MRD negativity to determine treatment level, neurological toxicities associated with certain treatments, utilization of specific treatments in medical oncology offices, advantages of bertimide vs. lintalitamide, and the examination of a treatment for multiple myeloma.